Document Type : Original Research
Authors
1 Department of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Biomedical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 Advanced Health Technologies Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
Background: A new treatment approach for most patients who have undergone early stage non-small-cell lung carcinoma (NSCLC) is wedge resection plus permanent implant brachytherapy. However, the specification of dose to medium at low energies especially in heterogeneous lung is unclear yet.
Objective: The present study aims to modify source strength for different configurations of 125I and 103Pd seeds used in lung permanent implant brachytherapy.
Methods: Different arrays of 125I and 103Pd seeds were simulated by MCNPX code in protocol-based water vs. actual 3D lung environments. Absorbed dose was, then, scored in both mediums. Dose differences between both environments were calculated and source strength was modified for the prescription point. In addition, lung-to-water absorbed dose ratio was obtained and presented by precise equations.
Results: Due to significant differences in prescription dose, source strength was modified 16%-19% and 37%-43% for different configurations of 125I and 103Pd seeds, respectively. In addition, depth-dependent dose differences were observed between the actual lung and protocol-based water mediums (dose difference as a function of depth).
Conclusion: Modification of source strength is essential for different arrangements of 125I and 103Pd seeds in lung implantation. Modified source strength and presented equations are recommended to be considered in future studies based on lung brachytherapy.
Keywords
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66. doi.org/10.3322/canjclin.57.1.43. PubMed PMID: 17237035.
- Lal R, Enting D, Kristeleit H. Systemic treatment of non-small-cell lung cancer. European Journal of Cancer. 2011;47:S375-S7. doi.org/10.1016/S0959-8049(11)70209-X.
- Devlin PM. Brachytherapy: applications and techniques: Springer Publishing Company; 2015.
- Voynov G, Heron DE, Lin CJ, Burton S, Chen A, Quinn A, et al. Intraoperative (125)I Vicryl mesh brachytherapy after sublobar resection for high-risk stage I non-small cell lung cancer. Brachytherapy. 2005;4:278-85. doi.org/10.1016/j.brachy.2005.03.007. PubMed PMID: 16344258.
- Sutherland JG, Furutani KM, Thomson RM. Monte Carlo calculated doses to treatment volumes and organs at risk for permanent implant lung brachytherapy. Phys Med Biol. 2013;58:7061-80. doi.org/10.1088/0031-9155/58/20/7061. PubMed PMID: 24051987.
- Sutherland J, Furutani K, Garces YI, Thomson R. Model-based dose calculations for 125I lung brachytherapy. Med Phys. 2012;39:4365-77. doi.org/10.1118/1.4729737. PubMed PMID: 24387504.
- S Sutherland JG, Miksys N, Furutani KM, Thomson RM. Metallic artifact mitigation and organ-constrained tissue assignment for Monte Carlo calculations of permanent implant lung brachytherapy. Med Phys. 2014;41:011712. doi.org/10.1118/1.4851555. PubMed PMID: 24387504.
- Johnson M, Colonias A, Parda D, Trombetta M, Gayou O, Reitz B, et al. Dosimetric and technical aspects of intraoperative I-125 brachytherapy for stage I non-small cell lung cancer. Phys Med Biol. 2007;52:1237-45. doi.org/10.1088/0031-9155/52/5/002. PubMed PMID: 17301451.
- Chen A, Galloway M, Landreneau R, d’Amato T, Colonias A, Karlovits S, et al. Intraoperative 125I brachytherapy for high-risk stage I non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1999;44:1057-63. doi.org/10.1016/S0360-3016(99)00133-9. PubMed PMID: 10421539.
- Venselaar J, Meigooni AS, Baltas D, Hoskin PJ. Comprehensive brachytherapy: physical and clinical aspects. Taylor & Francis: 2012.
- Santos R, Colonias A, Parda D, Trombetta M, Maley RH, Macherey R, et al. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer. Surgery. 2003;134:691-7; discussion 7. doi.org/10.1016/S0039-6060(03)00327-1. PubMed PMID: 14605631.
- Rivard MJ, Coursey BM, DeWerd LA, Hanson WF, Huq MS, Ibbott GS, et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31:633-74. doi.org/10.1118/1.1646040. PubMed PMID: 15070264.
- Rivard MJ, Butler WM, DeWerd LA, Huq MS, Ibbott GS, Meigooni AS, et al. Supplement to the 2004 update of the AAPM Task Group No. 43 Report. Med Phys. 2007;34:2187-205. doi.org/10.1118/1.2736790. PubMed PMID: 17654921.
- Measurements ICRU. Determination of absorbed dose in a patient irradiated by beams of x or gamma rays in radiotherapy procedures. International Commission on Radiation Units and Measurements (ICRUM:24): Washington DC; 1976.
- Van Dyk J, Keane TJ, Kan S, Rider WD, Fryer CJ. Radiation pneumonitis following large single dose irradiation: a re-evaluation based on absolute dose to lung. Int J Radiat Oncol Biol Phys. 1981;7:461-7. doi.org/10.1016/0360-3016(81)90131-0. PubMed PMID: 7251416.
- Sutherland JG. Monte Carlo dose calculations for breast and lung permanent implant brachytherapy: Carleton University Ottawa; 2013.
- Meigooni AS. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Medical physics. 1995;22:2.
- Taylor RE, Yegin G, Rogers DW. Benchmarking brachydose: Voxel based EGSnrc Monte Carlo calculations of TG-43 dosimetry parameters. Med Phys. 2007;34:445-57. doi.org/10.1118/1.2400843. PubMed PMID: 17388160.
- Woodard HQ, White DR. The composition of body tissues. Br J Radiol. 1986;59:1209-18. doi.org/10.1259/0007-1285-59-708-1209. PubMed PMID: 3801800.
- White DR, Woodard HQ, Hammond SM. Average soft-tissue and bone models for use in radiation dosimetry. Br J Radiol. 1987;60:907-13. doi.org/10.1259/0007-1285-60-717-907. PubMed PMID: 3664185.
- Mostaghimi H, Mehdizadeh AR, Darvish L, Akbari S, Rezaei H. Mathematical formulation of 125 I seed dosimetry parameters and heterogeneity correction in lung permanent implant brachytherapy. Journal of Cancer Research and Therapeutics. 2017. [in Press]
- Rivard MJ. Monte Carlo radiation dose simulations and dosimetric comparison of the model 6711 and 9011 I125 brachytherapy sources. Medical physics. 2009;36:486-91. doi.org/10.1118/1.3056463.
- Dolan J, Li Z, Williamson JF. Monte Carlo and experimental dosimetry of an I125 brachytherapy seed. Medical physics. 2006;33:4675-84. doi.org/10.1118/1.2388158. PubMed PMID: 17278820.
- Zabihzadeh M, Rezaee H, Shakarami Z, Feghhi M, Hosseini M. Dosimetric Characteristics of 103 Pd (Theragenices, Model 200) Brachytherapy Source. Biomed Pharmacol. 2015;8:15-23. doi.org/10.13005/bpj/550.
)